A new approach to antithrombotic therapy--evaluation of combined therapy of XXXX synthetase inhibitor and very low dose of @entity117 .

@entity1 @entity2871 @entity66 @entity63 @entity1423 @entity117 @entity1426 @entity17756
The effect of a selective @entity2871 (TX) synthetase inhibitor ( @entity17756 ), alone and in combination with a very low dose of @entity117 , on the platelet function was studied in healthy and diseased subjects. A single dose of 100 mg @entity17756 was orally administered to @entity1 with @entity63 ( @entity66 ) and healthy volunteers. TXB2 generation and @entity1423 were measured before and at 1, 4, 6 and 8hr after dosing. In addition, after the administration of a very low dose of @entity117 (0.1-0.25 mg/kg/day) for at least one month, a single dose of @entity17756 was given to @entity66 @entity1 . TXB2 generation and @entity1423 were measured in the same manner as @entity17756 alone. The effect of @entity17756 on @entity1423 induced by @entity1426 (AA) was different in each subject whereas platelet TXB2 generation was almost completely inhibited in all of the @entity1 and healthy volunteers. @entity17756 had a slight inhibitory effect on collagen induced aggregation. A combination of @entity17756 with a very low dose of @entity117 , on the other hand, produced additional inhibition of the @entity1423 induced by both AA and collagen. The present results suggest that the accumulation and metabolism of cyclooxygenase products that accumulate when TX synthetase is blocked, differ in each subject, additional inhibition is caused by the combined use of TX synthetase inhibitor and a very low dose of @entity117 because the very low dose of @entity117 partially reduces the proaggregatory cyclooxygenase products that accumulate when TX synthetase is blocked.(ABSTRACT TRUNCATED AT 250 WORDS)
